BofA raised the firm’s price target on Liquidia (LQDA) to $35 from $23 and keeps a Buy rating on the shares. The company reported solid 2Q results with an inventory stocking-driven sales beat, but more importantly, the management disclosed strong lead indicators for the Yutrepia launch that included over 550 new Yutrepia patient starts and over 900 unique prescription referrals, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia price target raised to $31 from $25 at Wells Fargo
- Promising Outlook for Liquidia Technologies: Strong Start for Yutrepia Drives Buy Rating
- Promising Market Launch and Growth Potential for Liquidia Technologies’ Yutrepia
- Liquidia reports Q2 EPS (49c), consensus (39c)
- LQDA Earnings this Week: How Will it Perform?